Focus Partners Wealth
IBRX icon

Focus Partners Wealth’s ImmunityBio IBRX Stock Holding History

Focus Partners Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Sell
263,233
-6,088
-2% -$46.1K ﹤0.01% 1296
2026
Q1 		$2.07M Buy
269,321
+215,363
+399% +$1.47M ﹤0.01% 1298
2025
Q4 		$107K Buy
+53,958
New +$122K ﹤0.01% 2541

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Focus Partners Wealth's IBRX Position: Q2 2026 in Review

Focus Partners Wealth reduced its ImmunityBio (IBRX) stake by 2.3% in Q2 2026, selling an estimated $46.1K and leaving 263,233 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Focus Partners Wealth first reported a position in IBRX in Q4 2025 and has held it in 3 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Focus Partners Wealth held 263,233 shares of ImmunityBio worth $2.3M as of Q2 2026.
  • Focus Partners Wealth sold 6,088 ImmunityBio shares in Q2 2026, an estimated $46.1K.
  • ImmunityBio made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1296 holding.
  • Focus Partners Wealth first reported a position in ImmunityBio in Q4 2025 and has held it in 3 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.